Extend Biosciences announces positive interim clinical data from the Phase 1 trial of EXT608 for the rare disease hypoparathyroidism.
News
A Second Manuscript Has Been Published on EXT418 for Cancer Cachexia
In collaboration with the laboratory of Jose Garcia, M.D., Ph.D. at the University of Washington, Extend Biosciences publishes a peer-reviewed article titled “EXT418, a novel long-acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice”.
A Foundational Manuscript on the D-VITylation Technology Has Been Published
The company’s first manuscript on the D-VITylation technology has been published in the International Journal of Pharmaceutics. It is titled “D-VITylation: Harnessing the biology of vitamin D to improve the pharmacokinetic properties of peptides and small proteins.”
-> A link to the article is here
MassVentures Awards Extend Biosciences with a START II Grant
A START II grant was awarded to Extend Biosciences in support of the Phase 1 clinical trial for EXT608. The company was one of only 5 awardees to receive the second phase of funding.
Extend Biosciences Begins Human Testing of EXT608
The Company is excited to announce that recruiting is ongoing for healthy volunteers to participate in Extend Biosciences’ Phase 1 trial of EXT608. The trial is being funded in-part by NIDDK.
->View the clinical trials.gov entry here
EXT608 Receives Orphan Drug Designation From FDA
FDA granted Orphan Drug Designation to Extend Biosciences’ EXT608 for the treatment of hypoparathyroidism.
Kate Didio Joins the Clinical Team at Extend Biosciences
Kate Didio, RN MBA, has joined Extend Biosciences as Clinical Program Lead, and will be responsible for all of the clinical operations and monitoring for the Phase 1 trial of EXT608. Ms. Didio has over 25 years of experience in clinical operations for biotech and pharmaceutical companies in multiple therapeutic areas, including pulmonary and metabolic diseases as well as orphan indications.
Extend Biosciences is Awarded a START Grant from MassVentures
Extend Biosciences’ EXT608 for hypoparathyroidism receives additional support from MassVentures’ START program, which helps growing Massachusetts-based companies convert research developed under SBIR and STTR contracts into businesses and jobs in Massachusetts.
Extend Biosciences Advances EXT608 to a Phase 1 Clinical Trial with a SBIR Phase IIB Award
NIDDK continues to fund Extend Biosciences’ long-acting PTH for hypoparathyroidism with a Phase IIB grant for the conduct of a Phase 1 trial in healthy volunteers.
Poul Strange Joins Extend Biosciences as Chief Medical Officer
Poul Strange, MD PhD, has joined the clinical team at Extend Biosciences to spearhead the Phase 1 trial of EXT608 in healthy volunteers. Dr. Strange is the Founder and serves as the Medical Director and President of Integrated Medical Development, a US full service clinical CRO focused assisting companies with their medical product development. IMD will be responsible for data management of the trial.